Download Image
    
Share
  
Post
Zunsemetinib for COVID-19
1 study with 20 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Zunsemetinib
No significant improvements are seen in meta analysis to date.
COVID-19 Zunsemetinib studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies 0% Mortality 0% RCTs 0% Late 0% Favorszunsemetinib Favorscontrol
Zunsemetinib (ATI-450) is an investigational, orally administered, small-molecule anti-inflammatory drug that inhibits the p38α→MK2 inflammatory signaling pathway, potentially reducing cytokine storm for COVID-19.
Jun 4
 Gan et al., NCT04481685 A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19
no change in mortality (p=1) and 25% higher progression (p=1). RCT 20 hospitalized patients showing no significant difference in outcomes with ATI-450 (zunsemetinib).